Ontario Court of Appeal allows Sanofi and Schering to plead that Federal Court ramipril patent invalidity decision was flawed due to “promise doctrine”

Published date03 December 2018
Law FirmSmart & Biggar
AuthorLynn Ing,Brandon Heard
Subject MatterRes Judicata,Appeals,Damages,Obviousness,Monopolization,AstraZeneca,Pleadings,Issue Preclusion,Reversal,Section 8,Pharmaceutical Patents,Trade Marks Act,Estoppel,Canada,Leave to Amend,Apotex,Patent Invalidity,Promise Doctrine,Sanofi,PMNOC Regulations,Collateral Attack,Statute of Monopolies

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT